SynopsisZalcitabine (CAS 7481-89-2) is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI). The global Zalcitabine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast pe.....
SynopsisBiochanin A (CAS 491-80-5) is a nitric oxide synthase inhibitor and apoptosis inducer. The global Biochanin A market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024.....
SynopsisSotrastaurin is a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. The global Sotrastaurin (PKC Inhibitor) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessi.....
SynopsisLoxoprofen sodium (CAS 80382-23-6) is a nonselective inhibitor of COX-1 and COX-2 that exhibits properties typical of most non-steroidal anti-inflammatory drugs (NSAIDs), including anti-inflammatory, analgesic, and antinociceptive activities. The global .....
SynopsisSolasodine is a potentially useful precursor for steroidal compounds and hormones, this is usually found in plants from the solanaceae family. The global Solasodine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030,.....
SynopsisOclacitinib is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. The global Oclacitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast.....
SynopsisFilgotinib is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. The global Filgotinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessin.....
SynopsisDecernotinib is a novel, potent, selective and orally available JAK3 inhibitor for the treatment of autoimmune diseases. The global Decernotinib (JAK3 Inhibitor) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, wi.....
SynopsisFedratinib is a selective inhibitor of JAK2.Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. The global Fedratinib market was valued at US$ million in 2023 and is anticipated to reach US$ million .....
SynopsisLestaurtinib inhibits JAK2, FLT3, and TrkA with IC50s of 0.9, 3, and less than 25 nM, respectively. Lestaurtinib is a multi-kinase inhibitor. It also has effective activity against the Trk family of receptor tyrosine kinases. The global Lestaurtinib mark.....
